Metabolic Dysregulation and Metabolite-Targeted Interventions in Autism Spectrum Disorder: Mechanisms and Translational Perspectives
- 1School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao 266000, China
- 2Jinan Institute of Child Health Care, Children’s Hospital Affiliated to Shandong University (Jinan Children’s Hospital), Jing-shi Road 23976, Jinan 250022, China
Abstract
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder marked by impaired social communication and restricted repetitive behaviors. Metabolic dysregulation is increasingly recognized as a key intermediate mechanism linking genetic and environmental factors to abnormal neurodevelopment in ASD. This review summarizes ASD-related metabolic abnormalities involving gut microbial metabolites, energy metabolism, neurotransmitter pathways, and immune–metabolic crosstalk. Such metabolic disturbances affect neurodevelopment via immune activation, oxidative stress, mitochondrial dysfunction, and disrupted neurotransmitter homeostasis, ultimately impairing synaptic plasticity and neural connectivity. We also outline the preclinical and clinical progress of metabolite-targeted interventions, which show potential to modulate relevant metabolic pathways. However, it should be noted that improvements in specific metabolic biomarkers may only be associated with, rather than definitively drive, behavioral changes. However, current studies are constrained by inconsistent trial designs, small cohorts, and inadequate mechanistic verification; furthermore, interindividual metabolic heterogeneity limits universal intervention efficacy. We discuss clinical translation barriers and propose future priorities: defining metabolic subtypes, validating biomarkers, and developing precision metabolic interventions. Elucidating these metabolic mechanisms will advance targeted, personalized therapies to improve neurodevelopmental outcomes in ASD.
Related
- The Role of NK‑Cell Dysregulation in Adverse Pregnancy Outcomes Associated with Rheumatic Immune Diseases: Mechanisms and Translational Advances
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
- GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives
- Umbilical cord blood mononuclear cells for inflammation-related diseases: a narrative review of immunomodulatory mechanisms, clinical evidence, and translational perspectives
- Phytochemistry, pharmacology, safety, and applications of Buddleja globosa Hope [Scrophulariaceae]: a systematic review from bioactive metabolites and mechanisms to translational perspectives
BibTeX
@article{fang2026metabolic,
title = {{Metabolic Dysregulation and Metabolite-Targeted Interventions in Autism Spectrum Disorder: Mechanisms and Translational Perspectives}},
author = {Yu Fang and Zechen Dou and Yanan Liu and Yishan Zong and Shengxiang Wang and Shangyong Li and Ningning He and Ning Li},
journal = {Metabolites},
year = {2026},
month = oct,
doi = {10.3390/metabo16100749},
url = {https://www.mdpi.com/2218-1989/16/10/749},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metabolic Dysregulation and Metabolite-Targeted Interventions in Autism Spectrum Disorder: Mechanisms and Translational Perspectives
AU - Yu Fang
AU - Zechen Dou
AU - Yanan Liu
AU - Yishan Zong
AU - Shengxiang Wang
AU - Shangyong Li
AU - Ningning He
AU - Ning Li
PY - 2026
DA - 2026/10/01
JO - Metabolites
DO - 10.3390/metabo16100749
UR - https://www.mdpi.com/2218-1989/16/10/749
AB - Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder marked by impaired social communication and restricted repetitive behaviors. Metabolic dysregulation is increasingly recognized as a key intermediate mechanism linking genetic and environmental factors to abnormal neurodevelopment in ASD. This review summarizes ASD-related metabolic abnormalities involving gut microbial metabolites, energy metabolism, neurotransmitter pathways, and immune–metabolic crosstalk. Such metabolic disturbances affect neurodevelopment via immune activation, oxidative stress, mitochondrial dysfunction, and disrupted neurotransmitter homeostasis, ultimately impairing synaptic plasticity and neural connectivity. We also outline the preclinical and clinical progress of metabolite-targeted interventions, which show potential to modulate relevant metabolic pathways. However, it should be noted that improvements in specific metabolic biomarkers may only be associated with, rather than definitively drive, behavioral changes. However, current studies are constrained by inconsistent trial designs, small cohorts, and inadequate mechanistic verification; furthermore, interindividual metabolic heterogeneity limits universal intervention efficacy. We discuss clinical translation barriers and propose future priorities: defining metabolic subtypes, validating biomarkers, and developing precision metabolic interventions. Elucidating these metabolic mechanisms will advance targeted, personalized therapies to improve neurodevelopmental outcomes in ASD.
SN - 2218-1989
ER -